论文部分内容阅读
纤溶已被确定为血管疾病病理生理方面的介体之一,同时也被认为是有益的治疗手段.因此,了解血浆素原活化剂的基本性质的重要性和血浆素原活化的分子机制的重要性更趋明显.生理性纤溶的特点是其特异性.相反,治疗性溶栓,即使使用新的激活剂,亦伴有非特异性蛋白溶解,这可能带来不利的副作用.Wiman和Collen为生理纤溶设计了一个模式,在这一模式中,血浆素原和纤维蛋白特异性结合为一种基本成份,它选择性地活化血浆素原,而剩下的非活化的血浆素原在其周围的血液中,这就是纤维蛋白特异性溶解的基本机制.在体外和某些动物模型中,这可以由血中天然血浆素原,组织血浆素原活化素(tissue plasminoger activator, t-PA)以及尿激
Fibrinolysis has been identified as one of the pathophysiological mediators of vascular disease and is also considered as a useful therapeutic approach.Therefore, understanding the importance of the basic properties of plasma pro-activators and the molecular mechanisms of plasma pro-activation The more obvious the importance of physiological fibrinolysis is characterized by its specificity.In contrast, therapeutic thrombolysis, even with the new activator, also associated with non-specific protein lysis, which may bring adverse side effects.Wiman and Collen A model has been designed for physiological fibrinolysis in which specific binding of plasminogen and fibrin is a fundamental component that selectively activates pro-plasminogen while the remaining non-activated plasma is This is the basic mechanism of fibrin-specific lysis in the bloodstream around it, which can be triggered by the blood plasma native procaspase, tissue plasminogen activator (t-PA ) And urinary irritation